Tal Teitz

6PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Neural engineeringWireless communication systems and technologies (incl. microwave and millimetrewave)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 27, 2024
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss.

Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann

|Jun 27, 2024
ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response.

Richard D Lutze, Matthew A Ingersoll, Alena Thotam

|Mar 28, 2024
KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss.

Matthew A Ingersoll, Richard D Lutze, Regina G Kelmann

|Nov 14, 2023
Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI.

Chithra K Pushpan, Daniel F Kresock, Matthew A Ingersoll

|Dec 03, 2020
BRAF inhibition protects against hearing loss in mice.

Matthew A Ingersoll, Emma A Malloy, Lauryn E Caster

Pageof 1